Holen Sie sich die Stockscreener-App
13.58
2.05%
-0.30
Schlusskurs vom Vortag:
$13.88
Offen:
$13.91
24-Stunden-Volumen:
35,663
Relative Volume:
0.56
Marktkapitalisierung:
$2.36B
Einnahmen:
$549.97M
Nettoeinkommen (Verlust:
$458.86M
KGV:
5.1761
EPS:
2.6236
Netto-Cashflow:
$-89.06M
1W Leistung:
+12.92%
1M Leistung:
+8.67%
6M Leistung:
-1.27%
1J Leistung:
-15.30%
1-Tages-Spanne:
$13.57
$13.91
1-Wochen-Bereich:
$13.51
$14.32
52-Wochen-Spanne:
$9.77
$18.30
Hutchmed China Limited Adr Stock (HCM) Company Profile
Compare HCM vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
13.59 | 2.41B | 549.97M | 458.86M | -89.06M | 2.6236 |
TAK
Takeda Pharmaceutical Co Adr
|
18.25 | 58.50B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.76 | 42.84B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.185 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.57 | 30.40B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
503.32 | 21.36B | 3.17B | 1.29B | 1.01B | 27.09 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-22 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-05-13 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-11-24 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-08-03 | Eingeleitet | Jefferies | Buy |
| 2020-10-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-03-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-20 | Eingeleitet | Goldman | Buy |
| 2019-11-19 | Eingeleitet | CLSA | Buy |
| 2019-10-23 | Bestätigt | BofA/Merrill | Buy |
| 2019-07-05 | Eingeleitet | Macquarie | Outperform |
Alle ansehen
Hutchmed China Limited Adr Aktie (HCM) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
Zai Lab LimitedADR Peer Comparison – Compare with Others - Value Research
China's Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy - BioSpectrum Asia
Trinity Delta Lighthouse: HUTCHMED - Vox Markets
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy - Yahoo Finance
HUTCHMED (NASDAQ:HCM) Shares Gap UpWhat's Next? - MarketBeat
Hutchmed Partners with GSK to Develop First-in-Class Cancer Drug in Licensing Deal Worth Up to $1.295 Billion - finance.biggo.com
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - Benzinga
GSK backs HUTCHMED (China) (HCM) cancer drug in deal topping $1 billion - Stock Titan
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
HUTCHMED (NASDAQ:HCM) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research
HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving AverageHere's Why - MarketBeat
HUTCHMED’s SANOVO Phase III Trial Demonstrates Significant PFS Advantage for ORPATHYS Plus TAGRISSO in First-Line EGFR-Mutated Lung Cancer - Kalkine Media
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China - Barchart.com
HUTCHMED (China) LimitedADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
China grants conditional OK to HUTCHMED (HCM) ATLED after 42.5% response - Stock Titan
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat
HUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeShould You Buy? - MarketBeat
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success - TradingView
HUTCHMED (HCM) flags director’s ex-role at firm in NIS3.1M insolvency case - Stock Titan
HUTCHMED (HCM) lung cancer combo extends survival after TAGRISSO - Stock Titan
ETFs Investing in HUTCHMED (China) Limited Sponsored ADR Stocks - TradingView
HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusDelta Hedging - vinanet.vn
HUTCHMED (NASDAQ:HCM) Share Price Crosses Above 50 Day Moving AverageHere's Why - marketbeat.com
REGHutchmed China LtdHUTCHMED Reports 2026 Interim Results - TradingView
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth - Yahoo Finance
A2AF74 Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (NASDAQ:HCM) Stock Price Down 6%Here's Why - MarketBeat
Sea Limited Sponsored ADR (SE) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Price to sales forward of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView
HCM Stock Price, Quote & Chart - ChartMill
Sea Limited Sponsored ADR (SE) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
NMPA clears HUTCHMED (HCM) drug ORPATHYS for MET-amplified gastric cancer - Stock Titan
HUTCHMED Announces NMPA Approval for ORPATHYS® for the - GlobeNewswire
Price to book forward of HUTCHMED (China) Limited Sponsored ADR – LSE:0J7G - TradingView
HUTCHMED (NASDAQ: HCM) schedules 2026 half-year results and investor webcasts - Stock Titan
HUTCHMED to Announce 2026 Half-Year Financial Results - GlobeNewswire
HUTCHMED (HCM) details 2015 and 2026 share option blocklisting return - Stock Titan
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LS:A2AF74) - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (GETTEX:H7T1) - TradingView
H7T1 Forecast — Price Target — Prediction for 2027 - TradingView
0J7G Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LSX:A2AF74) - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (NASDAQ:HCM) - TradingView
Pivotal fanregratinib ICC data and China NDA review for HUTCHMED (NASDAQ: HCM) - Stock Titan
RCSHutchmed China LtdHUTCHMED Highlights Phase II Data at ESMO - TradingView
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib - GlobeNewswire
HUTCHMED analyst targets stay high, shares trade well below consensus - ad-hoc-news.de
HUTCHMED Announces Phase III China Data from ESLIM-02 Study of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia - aastocks.com
Finanzdaten der Hutchmed China Limited Adr-Aktie (HCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):